# PBRM1

Source: https://onco.cc/targets/pbrm1/  
OnCo record `pbrm1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PBRM1 (polybromo 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Skin cancer, Biliary tract cancer and 5 more.

## Summary

Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). Acts as a negative regulator of cell proliferation.

CIViC holds 9 clinical evidence items and 0 assertions across 2 variants, naming Nivolumab, Everolimus, Pembrolizumab and Sunitinib and others. Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes genetic literature 0.61, affected pathway 0.83, literature 0.99, genetic association 0.63, somatic mutation 0.97). IntOGen calls it a driver in 23 cohorts (1 activating, 22 loss-of-function), covering Renal Clear Cell Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Gallbladder Cancer and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: polybromo 1; BAF180; PB1; SMARCH1
- Tags: cancer-genes-wave
- Symbol: PBRM1
- Class: transcription
- Biology: Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). Acts as a negative regulator of cell proliferation. Location: Nucleus (UniProt). Locus 3p21.1 (HGNC).
- Where found: Renal cell carcinoma: Open Targets association 0.74 with renal cell carcinoma (MONDO_0005086); CIViC evidence names this disease; Skin cancer: Open Targets association 0.64 with skin cancer (MONDO_0002898); Biliary tract cancer: Open Targets association 0.64 with biliary tract cancer (MONDO_0003060); CIViC evidence names this disease; Oesophageal cancer: IntOGen driver in 3 cohorts (ESCA); Mesothelioma: IntOGen driver in 2 cohorts (PLMESO); Cervical cancer: IntOGen driver in 1 cohort (CEAD)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 10 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 22 cohorts; CIViC holds 9 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:30064: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30064
- UniProt Q86U86: https://www.uniprot.org/uniprotkb/Q86U86/entry
- NCBI Gene 55193: https://www.ncbi.nlm.nih.gov/gene/55193
- Ensembl ENSG00000163939: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163939

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/pbrm1.json